Safety Evaluation of Omniscan: An Observational Postmarketing Surveillance.

Objective: This study aimed to conduct a single-arm, open-label, multicenter postmarketing surveillance study to evaluate the safety of Omniscan immediately and six weeks (± two weeks) after injection.

Methods: Three sites in India that use Omniscan (gadodiamide; GE Healthcare, Chicago, IL) as a contrast agent were selected. Omniscan is a linear, nonionic, nonprotein-binding gadolinium-based contrast agent.